Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CART-19 cells (Henan Cancer Hospital)
- Development stage
- Unknown
- Lead developer
- Henan Cancer Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
CART-19 cells (Henan Cancer Hospital) is an autologous chimeric antigen receptor (CAR) T-cell therapy developed by Henan Cancer Hospital for the treatment of relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (B-ALL). The therapy involves the genetic modification of a patient's own T cells to express a CAR that specifically targets the CD19 antigen, a surface protein ubiquitously expressed on B-cell lineage cells. Once re-infused into the patient following lymphodepleting chemotherapy (typically cyclophosphamide and fludarabine), these engineered cells recognize and eliminate CD19-expressing malignant B cells through T-cell mediated cytotoxicity.
- Other names
- anti-CD19 CAR-T cellsanti-CD-19 CAR-T cellsanti-CD 19 CAR-T cellsCD19-targeted CAR-T cellsCD-19-targeted CAR-T cellsCD 19-targeted CAR-T cellsCART-19 cells-Henan Cancer HospitalCART19 cells-Henan Cancer HospitalCART 19 cells-Henan Cancer Hospital
02
Targets
Beyond the preview
Go deeper on CART-19 cells (Henan Cancer Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CART-19 cells (Henan Cancer Hospital).